Sandbox: HCL therapy: Difference between revisions

VisualWikitext

Latest revision as of 02:16, 30 October 2015

Initial patients evaluation

History
Physical examination
Complete blood count

Asymptomatic patients with no therapeutic indications

Symptomatic patients or evidence of therapeutic indications

Patients managed by observation and close follow-up

Cladribine

Pentostatin

Complete response

No evidence of complete response

Follow-up and close observation

Retuximab alone
Interferon alpha alone

Alternative purine analogue ± rituximab

Relapse after one year: same initial purine analogue ± rituximab

Relapse before one year: alternative purine analogue ± rituximab

No evidence of complete response

Vemurafenib

@@ Line 2: / Line 2: @@
 {{familytree/start |summary=PE diagnosis Algorithm.}}
 {{familytree | | | | | | A02 | | | | | |A02=<div style="width: 10em; padding:0.2em;">'''Initial patients evaluation'''</div>}}
-{{familytree|boxstyle= border-top: 0px;| | | | | | A01 | | | | | | |A01=<div style="width: 15em; padding:1em;">History<br>Physical examination<br>Complete blood count</div>}}
+{{familytree|boxstyle= border-top: 0px;| | | | | | A01 | | | | | | |A01=<div style="width: 15em; padding:1em;text-align:center">History<br>Physical examination<br>Complete blood count</div>}}
 {{familytree | | | | | | |!| | | | | | | | | | | | }}
 {{familytree | | | | | | |!| | | | | | | | | | | | }}
 {{familytree | | | | |,|-|^|-|.| | | | | | }}
-{{familytree | | | | B02 | |B01| | |B02=<div style="width: 10em; padding:1em;">'''Asymptomatic patients with no therapeutic indications'''</div>|B01=<div style="width: 15em; padding:1em;">'''Symptomatic patients or evidence of therapeutic indications '''</div>}}
+{{familytree | | | | B02 | |B01| | |B02=<div style="width: 10em; padding:1em;text-align:center">'''Asymptomatic patients with no therapeutic indications'''</div>|B01=<div style="width: 15em; padding:1em;text-align:center">'''Symptomatic patients or evidence of therapeutic indications '''</div>}}
 {{familytree | | | | |!| | | |!| | | | }}
 {{familytree | | | | |!| | | |!| | | | }}
-{{familytree | | | | C02 | | C01| | |C01=<div style="width: 10em; padding:1em;">'''Manage with either [[cladribine]] or [[pentostatin]]'''</div>|C02=<div style="width: 15em; padding:1em;">'''Patients managed by observation and close follow-up'''</div>}}
+{{familytree | | | | C02 | | C01| | |C01=<div style="width: 10em; padding:1em;">
+'''[[Cladribine]]'''<br>
+'''[[Pentostatin]]'''</div>|C02=<div style="width: 15em; padding:1em;text-align:center">'''Patients managed by observation and close follow-up'''</div>}}
 {{familytree | | | | | | | | |!| | | | | | | | | | | | | }}
 {{familytree | | | | | | |,|-|^|-|.| | | | | | | | | | | }}
-{{familytree | | | | | | D02 | | D01 | | | | | | | | | |D01=<div style="width: 15em; padding:1em;">'''Frail patients (CIRS ≥6)'''</div>|D02=<div style="width: 15em; padding:1em;">'''Fit patients (CIRS <6)'''</div>}}
+{{familytree | | | | | | D02 | | D01 | | | | | | | | | |D01=<div style="width: 15em; padding:1em;text-align:center">'''No evidence of complete response'''</div>|D02=<div style="width: 15em; padding:1em;text-align:center">'''Complete response'''</div>}}
 {{familytree | | | | | | |!| | | |!| | | | | | | | | | | }}
 {{familytree | | | | | | |!| | | |!| | | | | | | | | | | }}
-{{familytree | | | | | | E02 | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:left">
+{{familytree | | | | | | E02 | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:center">
-'''[[Obinutuzumab]] {{and}} [[chlorambucil]]'''<br>
+'''[[Retuximab]] alone'''<br>
-'''[[Ofatumumab]] {{and}} chlorambucil'''<br>
+'''[[Interferon alpha]] alone'''<br>
-'''[[Rituximab]] {{and}} chlorambucil'''</div>|E02=<div style="width: 13em; padding:1em;">'''FISH chromosomal analysis'''</div>}}
+'''Alternative purine analogue {{withorwithout}} rituximab'''</div>|E02=<div style="width: 13em; padding:1em;text-align:center">'''Follow-up and close observation'''</div>}}
-{{familytree | | | | | | |!| | | | | | | | | | | | | | | }}
+{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }}
-{{familytree | | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | }}
+{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }}
-{{familytree | | G01 | | G02 | | G03 | | | | | | | | | | | | |G01=<div style="width: 13em; padding:1em;">'''Immunochemotherapeutic regimens for the management of patients without chromosome 17p deletion or chromosome 11q deletion can be found [[#Immunochemotherapeutic Regimens for the Management of Patients without Chromosome 17p Deletion or Chromosome 11q Deletion|'''here''']]'''</div>|G02=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for the management of patients with chromosome 17p deletion can be found [[#Immunochemotherapeutic Regimens for the Management of Patients with Chromosome 17p Deletion|'''here''']]'''</div>|G03=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for the management of patients with chromosome 11q deletion can be found [[#Immunochemotherapeutic Regimens for the Management of Patients with Chromosome 11q Deletion|'''here''']]'''</div>}}
+{{familytree | | | | | | E02 | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:center">'''No evidence of complete response'''</div>|E02=<div style="width: 13em; padding:1em;">
+'''Relapse after one year: same initial purine analogue ± rituximab'''<br>
+'''Relapse before one year: alternative purine analogue ± rituximab'''</div>}}
+{{familytree | | | | | | | | | | |!| | | | | | | | | | | }}
+{{familytree | | | | | | | | | | |!| | | | | | | | | | | }}
+{{familytree | | | | | | | | | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:lef">'''[[Vemurafenib]]'''</div>}}
 {{familytree/end}}
 <br>
-===Immun

Sandbox: HCL therapy: Difference between revisions

Latest revision as of 02:16, 30 October 2015

Navigation menu